ORIGUCHI Tomoki | Nagasaki University School of Health Sciences

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population
Autoimmune hepatitis in a patient with systemic lupus erythematosus : a case report
A case of Sjogren's syndrome presenting as hypokalemic myopathy due to distal renal tubular acidosis
A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis
Twenty-four-week follow-up examination of a leukocytapheresis therapy in rheumatoid arthritis
Characterization of anticytoplasmic antibodies in patients with systemic autoimmune diseases
A case of amyloidosis secondary to rheumatoid arthritis complicated with Graves' ophthalmopathy
Atypical mycobacteriosis in two patients with rheumatoid arthritis
Successful Combined Therapy of Cyclophosphamide and Cyclosporine for Acute Exacerbated Interstitial Pneumonia Associated with Dermatomyositis
Deep vein thrombosis and pulmonary thromboembolism in a patient with eosinophilia and obesity
Cutaneous vasculitis induced by TNF inhibitors : a report of three cases
Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics
Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables
Successful treatment of chronic lupus myocarditis with prednisolone and mizoribine
Contribution of an adenine to guanine single nucleotide polymorphism of the matrix metalloproteinase-13 (MMP-13) -77 promoter region to the production of anticyclic citrullinated peptide antibodies in patients with HLA-DRB1^*shared epitope-negative rheuma
Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor
In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline
Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab : comparison with the remission by the clinical disease activity index
Successful treatment of a patient with IgG4-related disease with a paravertebral mass lesion
Increased incidence of pre-diabetes mellitus at a department of rheumatology : a retrospective study
Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows and excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors
A patient with systemic lupus erythematosus who developed massive small intestinal hemorrhaging during treatment for chronic lupus peritonitis
Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration
A case of Sjogren's syndrome presenting as trigeminal nerve palsy
Thyroid papillary carcinoma with solid sclerosing change in IgG4-related sclerosing disease
Type B Insulin Resistance Complicated with Systemic Lupus Erythematosus

もっと見る

スポンサーリンク